Skip to main content
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. — Investor Relations & Filings

Ticker · CUE ISIN · US22978P1066 LEI · 549300PBW78KZA33WC97 US Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US CUE

About Cue Biopharma, Inc.

https://www.cuebiopharma.com/

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of injectable, engineered biologics to selectively modulate the human immune system. The company's proprietary platform creates therapeutics designed to mimic natural immune signals to precisely engage, expand, and activate specific, disease-relevant T cells. This targeted approach is being applied to develop immunotherapies for the treatment of cancer and autoimmune diseases, with the goal of restoring immune balance and providing effective treatments for serious conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-06-03 English
S-8
Regulatory Filings Classification · 85% confidence The document is a Form S-8 registration statement filed with the SEC under the Securities Act of 1933 for the company’s 2026 Stock Incentive Plan. Form S-8 is a regulatory compliance filing for the registration of securities issued under an employee benefit plan. It is not an earnings release, annual report, board change notice, or any other specific category listed. Therefore, it falls into the fallback category of general regulatory filings.
2026-06-03 English
S-3
Regulatory Filings Classification · 82% confidence The document is an SEC registration statement on Form S-3 (a shelf registration and prospectus for the resale of common stock by selling stockholders). It is not a corporate annual report (10-K), earnings release, MD&A, proxy or governance statement, or any other specific category. There is no dedicated category for SEC registration statements in the taxonomy, so it falls under the fallback category of general regulatory filings (RNS).
2026-06-03 English
8-K
Board/Management Information Classification · 88% confidence The document is a Form 8-K “Current Report” filed under the Exchange Act that discloses Item 5.02 (Departure and Election of Directors and Officers) and Item 8.01 (Other Events). All disclosures pertain to resignations of board members and appointments of new directors and senior officers (Chief Legal & Compliance Officer, Corporate Secretary, Principal Accounting Officer, etc.). There are no financial statements or earnings data, nor is it an invitation or proxy. This is a clear example of an announcement of changes in the company’s board of directors and senior management, which maps to “Board/Management Information.”
2026-06-02 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-21 English
8-K
Regulatory Filings
2026-05-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.